Perennial allergic rhinitis
Drug research and approvals for perennial allergic rhinitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 6 studies of perennial allergic rhinitis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 6
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- PollenVax Subcutaneous Immunotherapy for Mugwort Pollen-Induced Allergic RhinitisNCT07563439 · Phase 2 · Kazakh National Agrarian University · starts May 1, 2026
- Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or DfNCT07348302 · Phase 3 · Inmunotek S.L. · starts Apr 2, 2025
- Study to Evaluate the Efficacy and Safety of DW1807 in Perennial Allergic Rhinitis Patients With AsthmaNCT07168473 · Phase 3 · Daewon Pharmaceutical Co., Ltd. · starts Sep 9, 2024
- Validation of the Efficacy of Air Purifiers in Indoor Environment and Allergic Symptoms in Allergic Rhinitis PatientsNCT06890572 · Not applicable · Yonsei University · starts Mar 11, 2025
- Identification of B Regulatory Cells by Flow CytometryNCT06876506 · Not reported · Hull University Teaching Hospitals NHS Trust · starts Jan 21, 2026
- The Role of the Nasal Allergen Provocation Test in Starting and Monitoring Allergen ImmunotherapyNCT04544774 · Not reported · Universitaire Ziekenhuizen KU Leuven · starts Jul 16, 2020
Approved 12
- Fluticasone furoateGlucocorticoid receptor agonist
- CiclesonideGlucocorticoid receptor agonist
- CetirizineHistamine H1 receptor antagonist
- AzelastineHistamine H1 receptor antagonist
- DesloratadineHistamine H1 receptor antagonist
- Beclomethasone dipropionateGlucocorticoid receptor agonist
- MontelukastCysteinyl leukotriene receptor 1 antagonist
- BudesonideGlucocorticoid receptor agonist
- LoratadineHistamine H1 receptor antagonist
- LevocetirizineHistamine H1 receptor antagonist
- CarbinoxamineHistamine H1 receptor antagonist
- DexchlorpheniramineHistamine H1 receptor antagonist
Phase 3 12 of 17
- Mometasone furoateGlucocorticoid receptor agonist
- Fluticasone propionateGlucocorticoid receptor agonist
- Syrup
- LevocabastineHistamine H1 receptor antagonist
- BepotastineHistamine H1 receptor antagonist
- OlopatadineHistamine H1 receptor antagonist
- Mometasone
- EpinastineHistamine H1 receptor antagonist
- FexofenadineHistamine H1 receptor antagonist
- KetotifenHistamine H1 receptor antagonist
- PrednisoneGlucocorticoid receptor agonist
- FlunisolideGlucocorticoid receptor agonist
Phase 2 2
- DenufosolPurinergic receptor P2Y2 agonist
- Carbon dioxide
How its trials ended
173 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 47 whose ending is known, 87% met their primary endpoint, 2% missed it and 11% stopped early.
- Completed, result not reported11265%
- Met its primary endpoint4124%
- Status unknown85%
- Ongoing63%
- Stopped: enrollment or feasibility32%
- Stopped: other or unclear21%
- Missed its primary endpoint11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA